Pharmacological profile of MDL 26,024GO: A novel antiasthmatic agent

L. Baugh, W. Abraham, E. Matthews, P. Lahr

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

MDL 26,024GO was shown to be an orally absorbed mediator release inhibitor in the rat PCA and PPA tests. In addition, the compound was shown to both elicit and inhibit elicitation of the Bezold-Jarisch reflex in the dog. MDL 26,024GO also significantly reduced Ascaris-induced changes in pulmonary mechanics in cynomolgus monkeys. The compound inhibited both early and late phase antigen induced-changes in Ascaris-sensitive sheep, as well as the increased airway hyperreactivity which normally follows antigen challenge. These results suggest the compound may have therapeutic potential in the treatment of asthma.

Original languageEnglish
Pages (from-to)431-434
Number of pages4
JournalAgents and Actions
Volume27
Issue number3-4
DOIs
StatePublished - Jun 1 1989
Externally publishedYes

Fingerprint

Anti-Asthmatic Agents
Ascaris
Pharmacology
Antigens
Passive Cutaneous Anaphylaxis
Macaca fascicularis
Mechanics
Reflex
Rats
Sheep
Asthma
Dogs
Lung
Therapeutics
tetrazolast

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology (medical)

Cite this

Pharmacological profile of MDL 26,024GO : A novel antiasthmatic agent. / Baugh, L.; Abraham, W.; Matthews, E.; Lahr, P.

In: Agents and Actions, Vol. 27, No. 3-4, 01.06.1989, p. 431-434.

Research output: Contribution to journalArticle

Baugh, L, Abraham, W, Matthews, E & Lahr, P 1989, 'Pharmacological profile of MDL 26,024GO: A novel antiasthmatic agent', Agents and Actions, vol. 27, no. 3-4, pp. 431-434. https://doi.org/10.1007/BF01972843
Baugh, L. ; Abraham, W. ; Matthews, E. ; Lahr, P. / Pharmacological profile of MDL 26,024GO : A novel antiasthmatic agent. In: Agents and Actions. 1989 ; Vol. 27, No. 3-4. pp. 431-434.
@article{dfa0876ffb96499781e368d2f30c4b1a,
title = "Pharmacological profile of MDL 26,024GO: A novel antiasthmatic agent",
abstract = "MDL 26,024GO was shown to be an orally absorbed mediator release inhibitor in the rat PCA and PPA tests. In addition, the compound was shown to both elicit and inhibit elicitation of the Bezold-Jarisch reflex in the dog. MDL 26,024GO also significantly reduced Ascaris-induced changes in pulmonary mechanics in cynomolgus monkeys. The compound inhibited both early and late phase antigen induced-changes in Ascaris-sensitive sheep, as well as the increased airway hyperreactivity which normally follows antigen challenge. These results suggest the compound may have therapeutic potential in the treatment of asthma.",
author = "L. Baugh and W. Abraham and E. Matthews and P. Lahr",
year = "1989",
month = "6",
day = "1",
doi = "10.1007/BF01972843",
language = "English",
volume = "27",
pages = "431--434",
journal = "Inflammation Research",
issn = "1023-3830",
publisher = "Birkhauser Verlag Basel",
number = "3-4",

}

TY - JOUR

T1 - Pharmacological profile of MDL 26,024GO

T2 - A novel antiasthmatic agent

AU - Baugh, L.

AU - Abraham, W.

AU - Matthews, E.

AU - Lahr, P.

PY - 1989/6/1

Y1 - 1989/6/1

N2 - MDL 26,024GO was shown to be an orally absorbed mediator release inhibitor in the rat PCA and PPA tests. In addition, the compound was shown to both elicit and inhibit elicitation of the Bezold-Jarisch reflex in the dog. MDL 26,024GO also significantly reduced Ascaris-induced changes in pulmonary mechanics in cynomolgus monkeys. The compound inhibited both early and late phase antigen induced-changes in Ascaris-sensitive sheep, as well as the increased airway hyperreactivity which normally follows antigen challenge. These results suggest the compound may have therapeutic potential in the treatment of asthma.

AB - MDL 26,024GO was shown to be an orally absorbed mediator release inhibitor in the rat PCA and PPA tests. In addition, the compound was shown to both elicit and inhibit elicitation of the Bezold-Jarisch reflex in the dog. MDL 26,024GO also significantly reduced Ascaris-induced changes in pulmonary mechanics in cynomolgus monkeys. The compound inhibited both early and late phase antigen induced-changes in Ascaris-sensitive sheep, as well as the increased airway hyperreactivity which normally follows antigen challenge. These results suggest the compound may have therapeutic potential in the treatment of asthma.

UR - http://www.scopus.com/inward/record.url?scp=0024406096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024406096&partnerID=8YFLogxK

U2 - 10.1007/BF01972843

DO - 10.1007/BF01972843

M3 - Article

C2 - 2801334

AN - SCOPUS:0024406096

VL - 27

SP - 431

EP - 434

JO - Inflammation Research

JF - Inflammation Research

SN - 1023-3830

IS - 3-4

ER -